viewSativa Group PLC

Sativa Group PLC - DHSC & Home Office CBMP import relaxation welcomed

RNS Number : 8726E
Sativa Group PLC
03 March 2020

Press Release


3rd March 2020



Sativa Group Plc


("Sativa" or "the Company" or "the Group") 


Comment on faster access for patients to cannabis-based medicinal products (CBMPs) following relaxation of import restrictions by

the Department of Health and Social Care (DHSC) and the Home Office 


Yesterday the Department of Health and Social Care (DHSC) and the Home Office announced that patients will be able to get faster access to cannabis-based medicinal products (CBMPs) through the relaxation of import restrictions.  Sativa welcomes this initiative as it endorses the Group's view that the UK is fast-developing as a significant medicinal cannabis market in which it intends to extend its participation and maintain its position as the UK's leading quoted CBD wellness and medicinal cannabis Group. 


Sativa Chief Executive Henry Lees-Buckley said: "Yesterday's announcement by Matt Hancock, the Secretary of State for Health and Social Care, goes some way towards levelling the playing field and making cannabis-based remedies more affordable and accessible to all. 


"However, there is still a long way to go to bring the UK in parallel with other countries where the benefits of cannabis-based remedies have been accessible for many years and the UK's own medicinal cannabis industry remains very much fettered." 


Sativa is fortunate in holding one of the few Home Office Controlled Drug licences that allows it to cultivate, produce and supply cannabis for research purposes.  It allows the Group to fulfil its agreement with King's College London to supply the College with material as it researches the impact of cannabinoids on inflammation and respiratory diseases.  That runs in parallel with the Group's highly successful Goodbody CBD Wellness retail business and PhytoVista Laboratory service. 



-     Ends -


Media enquiries. 

Abchurch Communications

Julian Bosdet

+44 (0)207 4594 4070 

+44 (0) 7771 663 886 

[email protected]




For further information please contact: 


Henry Lees-Buckley 

Chief Executive Officer

Sativa Group Plc 

+44 (0) 20 7971 1255


[email protected]


Joseph Colliver

Chief Financial Officer

Sativa Group Plc 

+44 (0) 20 7971 1255


[email protected] 


NEX Exchange Corporate Adviser


Corporate Finance 

Stephen Keys / Max Gould 

Cenkos Securities plc 

+44 (0) 20 7397 8900



Equity Sales 

Julian Morse

Cenkos Securities

+44 (0) 20 7397 8900


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Sativa Group PLC

Price: -

Market: NEX
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Sativa Investments PLC acquires UK-based PhytoVista Laboratories

Geremy Thomas, chief executive of Sativa Investments PLC (NEX:SATI), tells Proactive's Andrew Scott they've agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000. The British medicinal cannabis investment vehicle will pay £235,000...

on 4/7/18